Participation of Opioid Pathway in the Central Antinociceptive Effects of Eugenol
International Journal of Oral Biology
; : 147-153, 2018.
Article
em Ko
| WPRIM
| ID: wpr-740074
Biblioteca responsável:
WPRO
ABSTRACT
The aim of the present study was to evaluate the central antinociceptive effects of eugenol after intraperitoneal administration. Experiments were carried out using male Sprague-Dawley rats. Subcutaneous injection of 5% formalin-induced nociceptive behavioral responses was used as the pain model. Subcutaneous injection of 5% formalin significantly produced nociceptive responses by increasing the licking time during nociceptive behavior. Subsequent intraperitoneal injection of 100 mg/kg of eugenol led to a significant decrease in the licking time. However, low dose of eugenol (50 mg/kg) did not affect the nociceptive behavioral responses produced by subcutaneous injection of formalin. Intrathecal injection of 30 µg of naloxone, an opioid receptor antagonist, significantly blocked antinociceptive effects produced by intraperitoneal injection of eugenol. Neither intrathecal injection of methysergide (30 µg), a serotonin receptor antagonist nor phentolamine (30 µg), an α-adrenergic receptor antagonist influenced antinociceptive effects of eugenol, as compared to the vehicle treatment. These results suggest that central opioid pathway participates in mediating the antinociceptive effects of eugenol.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Fentolamina
/
Injeções Espinhais
/
Eugenol
/
Serotonina
/
Negociação
/
Ratos Sprague-Dawley
/
Receptores Opioides
/
Formaldeído
/
Injeções Intraperitoneais
/
Injeções Subcutâneas
Limite:
Humans
/
Male
Idioma:
Ko
Revista:
International Journal of Oral Biology
Ano de publicação:
2018
Tipo de documento:
Article